Literature DB >> 18396081

Botulinum toxin injection with and without electromyographic assistance for treatment of abducens nerve palsy: a pilot study.

Mostafa Soltan Sanjari1, Khalil Ghasemi Falavarjani, Mohsen Bahmani Kashkouli, Gholam Hosseyn Aghai, Marzieh Nojomi, Hatav Rostami.   

Abstract

PURPOSE: To compare the effects and complications of botulinum toxin injection into the medial rectus muscle with and without electromyographic (EMG) assistance for treatment of abducens nerve palsy.
METHODS: In a prospective, comparative, interventional case series, botulinum toxin was injected into the medial rectus muscle of 23 patients with esotropia secondary to abducens nerve palsy within 3 months of onset. Patients were randomly assigned to two groups. The injection was given with EMG assistance in the first (EMG group) and without EMG in the second group (no-EMG group). Success was defined as a distance esotropia of no more than 10(Delta) in the primary position. Angle of deviation was recorded preoperatively and at 1 week, 3 months, and 6 months; any postoperative complications and side effects were noted.
RESULTS: There were 11 patients in the EMG and 12 patients in the no-EMG group. The ocular deviations were significantly improved in both groups with an overall 6 month success rate of 52.2% (p = 0.008 in the EMG group, p = 0.006 in the no-EMG group). Success rates and mean changes of the angle of deviation were not statistically different between the two groups. Postinjection blepharoptosis was found to be significantly more in the EMG group (p = 0.009).
CONCLUSIONS: The effectiveness of botulinum toxin injection is the same with or without EMG assistance into the medial rectus muscle for treatment of abducens nerve palsy. EMG assistance is associated with more blepharoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18396081     DOI: 10.1016/j.jaapos.2007.11.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  8 in total

1.  Use of Botulinum Toxin in Ophthalmology.

Authors:  Michael J Wan; Sara AlShaker; David G Hunter
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  Botulinum toxin for the treatment of strabismus.

Authors:  Fiona J Rowe; Carmel P Noonan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-02

3.  Efficacy of intraorbital electroacupuncture for diabetic abducens nerve palsy: study protocol for a prospective single-center randomized controlled trial.

Authors:  Ling-Yun Zhou; Xue-Mei Li; Tie-Juan Liu; Xiao-Jie Ji; Ming Zhao; Chang Su; Ji-Chao Liu; Jiang-Yun Sun
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

4.  Botulinum toxin injection in the patients with Duane syndrome type 1.

Authors:  Ahmad Ameri; Farzad Farzbod; Fatemeh Bazvand; Arash Mirmohammadsadeghi; Mohammadreza Akbari; Faramarz Anvari; Simindokht Hosseini
Journal:  J Curr Ophthalmol       Date:  2016-11-12

5.  Botulinum toxin A in the early treatment of sixth nerve palsy in type 2 diabetes.

Authors:  Sandra Ganesh; Sasikala Elizabeth Anilkumar; Kalpana Narendran
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

6.  Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.

Authors:  Nitika Pandey; Siddharth Agrawal; Rajat M Srivastava; Vinita Singh
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

7.  Botulinum toxin injection without electromyographic guidance in consecutive esotropia.

Authors:  Hee Kyung Yang; Dong Hyun Kim; Jeong-Min Hwang
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

8.  Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness.

Authors:  Hongjia Xu; Weifeng Sun; Shuying Dai; Yanyan Cheng; Jing Zhao; Yuan Liu; Juan Wang; Ya'nan Wang; Yu Gao; Huifang Han; Aijun Han
Journal:  J Ophthalmol       Date:  2020-12-31       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.